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Portacaval Shunt for Portal Hypertensive Gastropathy
ABSTRACT
Orloff, M. J., Orloff, M. S., Orloff, S. L. and Haynes, K. S.
(1995) Treatment of bleeding from portal hypertensive
gastropathy by portacaval shunt. Hepatology; 21,
1011-1017.
Portal hypertensive gastropathy is a vascular dis-
order of the gastric mucosa distinguished by ectasia
of the mucosal capillaries and submucosal veins
without inflammation. During 1988 to 1993, 12
patients with biopsyproven cirrhosis (10 alcoholic,
2 posthepatitic) were evaluated and treated prospec-
tively by portacaval shunt for active bleeding from
severe portal hypertensive gastropathy. Eleven pa-
tients had been hospitalized for bleeding three to
nine times previously, and one was bleeding un-
controllably for the first time. Requirement for
blood transfusions ranged from 11 to 39 units
cumulatively, of which 8 to 30 units were required
specifically to replace blood lost from portal hyper-
tensive gastropathy. Admission findings were as-
cites in 9 patients, jaundice in 8, severe muscle
wasting in 10, hyperdynamic state in 9. Child’s risk
class was C in 7, B in 4, A in 1. Ten of the 12 patients
had previously received repetitive endoscopic sclero-
therapy for esophageal varices, which has been
reported to precipitate portal hypertensive gastro-
pathy. Eight patients had failed propranolol therapy
for bleeding. Portacaval shunt was performed
emergently in 11 patients and electively in 1, and
permanently stopped bleeding in all by reducing the
mean portal vein-inferior vena cava pressure gradi-
ent from 251 to 16 mm saline. There were no
operative deaths, and two unrelated late deaths after
13 and 24 months. During 1 to 6.75 years of follow-
up, all shunts remained patent by ultrasonography,
the gastric mucosa reverted to normal On serial
endoscopy, and there was no gastrointestinal bleed-
ing. Recurrent portal-systemic encephalopathy de-
veloped in only 8% of patients. Quality of life was
generally good. It is concluded that portacaval shunt
provides definitive treatment of bleeding portal
hypertensive gastropathy by eliminating the under-
lying cause, and makes possible prolonged survival
with an acceptable quality of life. (Hepatology 1995;
21, 1011-1017.)
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PAPER DISCUSSION
In this paper, the senior Orloff and colleagues
propose an additional indication for their pre-
ferred surgical operation, the total portacaval
shunt [1]. Portalhypertensive gastropathy (PHG),
as Orloff points out, is a recently-characterized
lesion thatmay result in significant (albeit usually
not massive) upper gastrointestinal hemorrhage
[2-4]. Orloff et al. accrued 12 patients over a 5
year period with PHG associated with bleeding
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thatwas deemed severe enough to warrant opera-
tive intervention [1].
The pathophysiolgy of PHG is distinct from
that of gastritis [2], although the earliest reports
of portal decompression to treat PHG referred to
it as "erosive gastritis" or "hemorrhagic gastri-
tis" for want of a better term [5-7]. Subsequent
investigations have shown that the pathogenesis
of PHG is a consequence of adverse events in the
gastric mucosal microvasculature [8-10]. Gas-
tritis, by contrast, is primarily an inflammatory
phenomenon [21.
Ongoing work at the basic science level
continues to elucidate the functional and struc-
tural features of the portal hypertensive gastric
mucosa that result in PHG [8-12]. Animal
models of PHG and a few preliminary studies in
humans have demonstrated that submucosal
edema, venous ectasia and hypo-oxygenation of
the gastric mucosal surface are observed consis-
tently. An important additional feature is gastric
mucosal microvasculopathy, characterized by
hypertrophy of capillary endothelial cells with
diminished cross-sectional area of the capillary
lumen, which may account for the local hypo-
oxygenation and compromised defensive barrier
function. The latter is characterized by increased
back-diffusion of hydrogen ions and increased
susceptibility to damage by noxious agents such
as alcohol and aspirin [12].
A recent consensus conference sponsored by
the New Italian Endoscopic Club (NIEC) con-
cluded that PHG is a clinically significant lesion,
though more commonly associated with chronic
than acute blood loss [13]. Propranolol and
other nonselective beta-adrenergic antagonists
were suggested as a means to diminish the
probability of bleeding from PHG. Surgical
portacaval shunts, especially total shunts (as in
Orloff’s series) were considered to be indicated
for managing refractory disease.
In the present study, Orloff points out that
endoscopic sclerotherapy of esophageal varices
has been observed to precipitate PHG or make it
worse [1,3]. Presumably, other methods that do
not act to reduce intragastric venous pressure,
such as endoscopic or surgical variceal ligation,
will suffer from the same limitation. The
substitution of congested gastric mucosal micro-
vessels for congested esophageal macrovessels
was an unanticipated complication of ablative
treatments that has only recently come to light
as PHG was recognized as a distinct clinical
entity [3].
To focus excessively on either the indication
or the specifics of the operation, though, may be
to miss the point. Orloff has another message:
when a patient presents with life-threatening
hemorrhage, speed matters. Orloff’s clinical
practice setting represents a remarkable and
unique situation. At the University of California,
San Diego (UCSD), Orloff and his team take
immediate control of all patients with portal
hypertensive upper gastrointestinal bleeding.
Within eight hours [1], such patients undergo
definitive surgical decompression of the portal
circulation with consequent cessation of hemor-
rhage. Implicit in this scheme is that patients also
are afforded prompt, definitive airway control,
ongoing fluid resuscitation, correction of coagu-
lopathy, and maintenance ofnormothermia. In an
editorial accompanying Orloff’s paper, Conn 14]
suggests that the speed with which the UCSD
team addresses the physiologic derangement of
severe portal hypertensive bleeding may be the
most significant aspect of treatment. We agree.
While other workers in the field of portal
hypertension advocate a variety of emerging,
less invasive procedures such as variceal ligation
and TIPS, Orloff’s contrarian approach is to
continue to find new indications for a time-
tested operation [1]..As he expands his long-
running clinical series from bleeding esophageal
varices to bleeding portal hypertensive gastro-
pathy, the consistency of his phenomenal clinical
success is somehow reassuring.
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Is there a Role for Radical Surgery
in Advanced Gallbladder Carcinoma?
ABSTRACT
Miyazaki, M., Itoh, H., Ambiru, S., Shimizu, H., Togawa,
A., Gohchi, E., Nakajima, N. and Suwa, T. (1996) Radical
surgery for advanced gallbladder carcinoma. British Journal
of Surgery; 83, 478 481.
Forty-four patients with advanced gallbladder carci-
noma (18 with stage pT3 and 26 with stage pT4 of the
Union Internacional Contra la Cancrum classifica-
tion) were aggressively managed by extended
heptatic resection in 33 patients, bile duct resection
in 28, pancreaticoduodenectomy in seven, gastro-
intestinal resection in eleven and portal vein resec-
tion and reconstruction in seven. Adjacent organ
involvement was classified as follows: type I,
hepatic involvement with or without gastrointest-
inal invasion (Ia, Ib); type II, bile duct involvement
with or without gastrointestinal invasion (IIa, IIb);
type III, hepatic and bile duct involvement with or
without gastrointestinal invasion (IIIa, IIIb); type
IV, gastrointestinal involvement without hepatic or
bile duct invasion. Fourteen of 15 patients with type
I tumours had a curative resection compared with
seven of 26 with type III lesions (P< 0.0001). The
surgical mortality rate was two of 15 patients with
type I tumours, seven of 26 with type III tumours
and nine of 44 for the whole group. The long-term
survival rate after curative resection was four and
two of 23 at 3 and 5 years respectively, significantly
better than two and none of 21 at I and 2 years after